Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Adrenocortical Carcinoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Paraganglioma 1Osteosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasm Metastasis 1Insulinoma 1Hepatoblastoma 1Glucagonoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Carcinoma 1Carcinoid Tumor 1

Interventions

Everolimus 3Sunitinib 2Octreotide 2repotrectinib 1pralsetinib 1pasireotide 1lutetium Lu 177 dotatate 1epothilone B 1cixutumumab 1belinostat 1azaspirane 1avelumab 1Radiotherapy 1Lutetium-177 1Etoposide 1Doxorubicin 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × cixutumumab × Endocrine × Clear all
NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Eli Lilly and Company

Phase 2 Completed
43 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡